Ohtuvayre (Ensifentrine)-When will Ensifentrine be approved in China?

Ohtuvayre (Ensifentrine) - Ensifentrine is a new drug primarily used to treat chronic obstructive pulmonary disease (COPD). COPD is a common chronic lung disease. Patients usually experience symptoms such as difficulty breathing, coughing, and excessive phlegm, which seriously affects the quality of life. As a first-in-class selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), exefantine's unique mechanism of action enables it to effectively improve the symptoms of COPD patients.

Exefentine acts directly on the lungs to promote bronchodilation while reducing inflammation. The importance of this mechanism of action is that it not only helps patients relieve dyspnea, but also reduces chronic inflammation caused by COPD and reduces the risk of acute exacerbations. By inhaling the drug, exefantine can achieve higher drug concentrations directly into the lungs, effectively improving the drug's efficacy. Therefore, this drug is expected to provide a safer and more effective treatment option for COPD patients.

So far, ensefentin has been approved by the U.S. Food and Drug Administration (FDA) and will be officially launched on June 26, 2024. However, in the Chinese market, there is currently no relevant news indicating that the drug has been approved for marketing. As the global demand for COPD treatment continues to rise, more and more patients hope to have access to this new drug as soon as possible.

The Chinese drug regulatory agency is expected to review exefantine in the future. If it can successfully pass the review, ensefentin will bring new treatment hope to domestic COPD patients and enrich existing treatments. It is worth noting that the approval time of a drug is affected by many factors, including the completeness of clinical data, the process of drug registration application, and changes in the policy environment. Therefore, it is currently impossible to accurately predict the specific launch time of Ensefentine in China.

Reference materials:https://en.wikipedia.org/wiki/Ensifentrine